CA2713839A1 - Methods and kits for the rapid determination of patients at high risk of death during septic shock - Google Patents
Methods and kits for the rapid determination of patients at high risk of death during septic shock Download PDFInfo
- Publication number
- CA2713839A1 CA2713839A1 CA2713839A CA2713839A CA2713839A1 CA 2713839 A1 CA2713839 A1 CA 2713839A1 CA 2713839 A CA2713839 A CA 2713839A CA 2713839 A CA2713839 A CA 2713839A CA 2713839 A1 CA2713839 A1 CA 2713839A1
- Authority
- CA
- Canada
- Prior art keywords
- hla
- drb4
- genes
- areg
- fosb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 90
- 206010040070 Septic Shock Diseases 0.000 title claims abstract description 40
- 230000036303 septic shock Effects 0.000 title claims abstract description 39
- 230000034994 death Effects 0.000 title description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 144
- 230000014509 gene expression Effects 0.000 claims abstract description 84
- -1 LOC96610 Proteins 0.000 claims abstract description 52
- 206010053159 Organ failure Diseases 0.000 claims abstract description 39
- 102100036034 Thrombospondin-1 Human genes 0.000 claims abstract description 39
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 claims abstract description 38
- 206010040047 Sepsis Diseases 0.000 claims abstract description 37
- 101000931462 Homo sapiens Protein FosB Proteins 0.000 claims abstract description 35
- 101001035752 Homo sapiens Hydroxycarboxylic acid receptor 3 Proteins 0.000 claims abstract description 34
- 102100039356 Hydroxycarboxylic acid receptor 3 Human genes 0.000 claims abstract description 34
- 102100020847 Protein FosB Human genes 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 101001128500 Homo sapiens Marginal zone B- and B1-cell-specific protein Proteins 0.000 claims abstract description 33
- 101001096330 Homo sapiens Retinoid-binding protein 7 Proteins 0.000 claims abstract description 33
- 102100031826 Marginal zone B- and B1-cell-specific protein Human genes 0.000 claims abstract description 33
- 102100037879 Retinoid-binding protein 7 Human genes 0.000 claims abstract description 33
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims abstract description 30
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims abstract description 29
- 102100035266 Phosphatase and actin regulator 2 Human genes 0.000 claims abstract description 27
- 102100022633 Fructose-2,6-bisphosphatase Human genes 0.000 claims abstract description 26
- 101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 claims abstract description 26
- 102100030131 Interferon regulatory factor 5 Human genes 0.000 claims abstract description 26
- 102100027303 Interferon-induced protein with tetratricopeptide repeats 2 Human genes 0.000 claims abstract description 26
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 claims abstract description 26
- 102100032045 E3 ubiquitin-protein ligase AMFR Human genes 0.000 claims abstract description 25
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims abstract description 25
- 101000823467 Homo sapiens Fructose-2,6-bisphosphatase Proteins 0.000 claims abstract description 25
- 108010052199 HLA-C Antigens Proteins 0.000 claims abstract description 24
- 101000879661 Homo sapiens Chitotriosidase-1 Proteins 0.000 claims abstract description 21
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims abstract description 21
- 102100037328 Chitotriosidase-1 Human genes 0.000 claims abstract description 19
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 18
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 18
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 claims abstract description 17
- 108010040960 HLA-DRB4 Chains Proteins 0.000 claims abstract description 17
- 102100039621 Epithelial-stromal interaction protein 1 Human genes 0.000 claims abstract description 15
- 101000814134 Homo sapiens Epithelial-stromal interaction protein 1 Proteins 0.000 claims abstract description 15
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims abstract description 11
- 102100038778 Amphiregulin Human genes 0.000 claims abstract 15
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 claims abstract 15
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims abstract 12
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims abstract 12
- GXAFMKJFWWBYNW-OWHBQTKESA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC2CC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GXAFMKJFWWBYNW-OWHBQTKESA-N 0.000 claims abstract 10
- 101000776154 Homo sapiens E3 ubiquitin-protein ligase AMFR Proteins 0.000 claims abstract 10
- 101001011442 Homo sapiens Interferon regulatory factor 5 Proteins 0.000 claims abstract 10
- 101001082058 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 2 Proteins 0.000 claims abstract 10
- 101001094028 Homo sapiens Phosphatase and actin regulator 2 Proteins 0.000 claims abstract 10
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims abstract 10
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims abstract 8
- 239000000523 sample Substances 0.000 claims description 39
- 102100026921 Immunoglobulin lambda variable 1-44 Human genes 0.000 claims description 18
- 238000004393 prognosis Methods 0.000 claims description 18
- 230000003321 amplification Effects 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 210000000265 leukocyte Anatomy 0.000 claims description 8
- 101800004937 Protein C Proteins 0.000 claims description 7
- 101800001700 Saposin-D Proteins 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 238000010837 poor prognosis Methods 0.000 claims description 7
- 229960000856 protein c Drugs 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 230000003828 downregulation Effects 0.000 claims description 6
- 229940126601 medicinal product Drugs 0.000 claims description 6
- 230000003827 upregulation Effects 0.000 claims description 6
- 108020004463 18S ribosomal RNA Proteins 0.000 claims description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 230000009286 beneficial effect Effects 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 101001054838 Homo sapiens Immunoglobulin lambda variable 1-44 Proteins 0.000 claims 8
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 2
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 238000011156 evaluation Methods 0.000 abstract description 7
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 238000004458 analytical method Methods 0.000 abstract description 3
- 102000007299 Amphiregulin Human genes 0.000 description 28
- 108010033760 Amphiregulin Proteins 0.000 description 28
- 238000002493 microarray Methods 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 20
- 102000008236 Toll-Like Receptor 7 Human genes 0.000 description 20
- 238000003205 genotyping method Methods 0.000 description 20
- 101710097094 Phosphatase and actin regulator 2 Proteins 0.000 description 17
- 101710157897 Interferon regulatory factor 5 Proteins 0.000 description 16
- 101710166698 Interferon-induced protein with tetratricopeptide repeats 2 Proteins 0.000 description 16
- 238000010238 partial least squares regression Methods 0.000 description 16
- 101710094160 E3 ubiquitin-protein ligase AMFR Proteins 0.000 description 15
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 14
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 14
- 101710197212 Interferon-induced protein 44 Proteins 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 238000003753 real-time PCR Methods 0.000 description 11
- 108700028369 Alleles Proteins 0.000 description 10
- 101150084888 HLA-DRB4 gene Proteins 0.000 description 10
- 101710169443 Immunoglobulin lambda variable 1-44 Proteins 0.000 description 10
- 238000012706 support-vector machine Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 108020004394 Complementary RNA Proteins 0.000 description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 description 8
- 102000006354 HLA-DR Antigens Human genes 0.000 description 8
- 239000003184 complementary RNA Substances 0.000 description 8
- 101100117565 Oryza sativa subsp. japonica DRB4 gene Proteins 0.000 description 7
- 102100026534 Procathepsin L Human genes 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 101000983583 Homo sapiens Procathepsin L Proteins 0.000 description 6
- 101000984533 Homo sapiens Ribosome biogenesis protein BMS1 homolog Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000017975 Protein C Human genes 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002790 cross-validation Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000013614 RNA sample Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003633 gene expression assay Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 101150034979 DRB3 gene Proteins 0.000 description 3
- 101150095529 DRB4 gene Proteins 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229940042040 innovative drug Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 101150082328 DRB5 gene Proteins 0.000 description 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101100117569 Oryza sativa subsp. japonica DRB6 gene Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 206010053879 Sepsis syndrome Diseases 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000009762 endothelial cell differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 101150094083 24 gene Proteins 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 101100204264 Arabidopsis thaliana STR4 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 101100178984 Caenorhabditis elegans hyl-2 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 101710151413 Chitinase 1 Proteins 0.000 description 1
- 101710132290 Chitotriosidase-1 Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710107327 Endochitinase 1 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101100218845 Escherichia coli (strain K12) bioH gene Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 101710097738 HLA class II histocompatibility antigen, DR beta 4 chain Proteins 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 108700005092 MHC Class II Genes Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 101100182718 Mus musculus Ly6d gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101000983576 Paramecium tetraurelia Cathepsin L 2 Proteins 0.000 description 1
- 108010022678 Phosphofructokinase-2 Proteins 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101710097927 Retinal-binding protein Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100027057 Ribosome biogenesis protein BMS1 homolog Human genes 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101150076149 TROL gene Proteins 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 101710177717 Terminase small subunit Proteins 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 101710187885 Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 101150029327 bioB gene Proteins 0.000 description 1
- 101150085692 bioC gene Proteins 0.000 description 1
- 101150023452 bioD gene Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 101150036876 cre gene Proteins 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000002635 electroconvulsive therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- UXDAWVUDZLBBAM-UHFFFAOYSA-N n,n-diethylbenzeneacetamide Chemical compound CCN(CC)C(=O)CC1=CC=CC=C1 UXDAWVUDZLBBAM-UHFFFAOYSA-N 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012628 principal component regression Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102000024458 retinal binding proteins Human genes 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290090A EP2085486A1 (en) | 2008-02-01 | 2008-02-01 | Methods and kits for the rapid determination of patients at high risk of death during septic shock |
| EP08290090.3 | 2008-02-01 | ||
| US4391408P | 2008-04-10 | 2008-04-10 | |
| US61/043,914 | 2008-04-10 | ||
| PCT/IB2009/000292 WO2009095786A2 (en) | 2008-02-01 | 2009-01-30 | Methods and kits for the rapid determination of patients at high risk of death during septic shock |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2713839A1 true CA2713839A1 (en) | 2009-08-06 |
Family
ID=39590402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2713839A Abandoned CA2713839A1 (en) | 2008-02-01 | 2009-01-30 | Methods and kits for the rapid determination of patients at high risk of death during septic shock |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110190143A1 (enExample) |
| EP (2) | EP2085486A1 (enExample) |
| JP (1) | JP2011510650A (enExample) |
| CA (1) | CA2713839A1 (enExample) |
| WO (1) | WO2009095786A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010049818A1 (en) * | 2008-10-28 | 2010-05-06 | Assistance Publique - Hopitaux De Paris | Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock |
| US8283131B2 (en) | 2008-10-28 | 2012-10-09 | Assistance Publique-Hopitaux De Paris | Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock |
| JP2013536678A (ja) * | 2010-09-03 | 2013-09-26 | コンファルマ・フランス | リアルタイム定量ｐｃｒによる残留宿主細胞ｄｎａの定量 |
| US9938557B2 (en) | 2010-09-16 | 2018-04-10 | The General Hospital Corporation | Red blood cell dynamics for administering treatment for iron-deficiency anemia |
| WO2012068519A2 (en) * | 2010-11-19 | 2012-05-24 | Sirius Genomics Inc. | Markers associated with response to activated protein c administration, and uses thereof |
| WO2013119871A1 (en) | 2012-02-07 | 2013-08-15 | Children's Hospital Medical Center | A multi-biomarker-based outcome risk stratification model for pediatric septic shock |
| WO2013119869A1 (en) | 2012-02-07 | 2013-08-15 | Children's Hospital Medical Center | A multi-biomarker-based outcome risk stratification model for adult septic shock |
| WO2015073665A1 (en) * | 2013-11-13 | 2015-05-21 | The General Hospital Corporation | Methods and assays relating to the treatment of infection |
| EP3074536B1 (en) | 2013-11-25 | 2019-06-19 | Children's Hospital Medical Center | Temporal pediatric sepsis biomarker risk model |
| WO2015135071A1 (en) * | 2014-03-14 | 2015-09-17 | Hancock Robert E W | Diagnostic for sepsis |
| US20170108487A1 (en) * | 2014-06-05 | 2017-04-20 | The General Hospital Corporation | Predicting morbidity associated with red blood cell volume variance |
| US10261068B2 (en) | 2015-06-04 | 2019-04-16 | Children's Hospital Medical Center | Persevere-II: redefining the pediatric sepsis biomarker risk model with septic shock phenotype |
| WO2017106461A1 (en) | 2015-12-15 | 2017-06-22 | The General Hospital Corporation | Methods of estimating blood glucose and related systems |
| US11293852B2 (en) | 2016-04-07 | 2022-04-05 | The General Hospital Corporation | White blood cell population dynamics |
| WO2019173647A1 (en) * | 2018-03-08 | 2019-09-12 | University Of Notre Dame Du Lac | Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and adminstering treatment protocols based thereon |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7267945B2 (en) * | 2001-03-26 | 2007-09-11 | Applera Corporation | Methods of determining the presence of polynucleotides employing amplification |
| FR2881437B1 (fr) * | 2005-01-31 | 2010-11-19 | Biomerieux Sa | Procede pour le diagnostic/pronostic d'un syndrome septique |
-
2008
- 2008-02-01 EP EP08290090A patent/EP2085486A1/en not_active Withdrawn
-
2009
- 2009-01-30 EP EP09705033A patent/EP2245194A2/en not_active Withdrawn
- 2009-01-30 US US12/865,536 patent/US20110190143A1/en not_active Abandoned
- 2009-01-30 WO PCT/IB2009/000292 patent/WO2009095786A2/en not_active Ceased
- 2009-01-30 CA CA2713839A patent/CA2713839A1/en not_active Abandoned
- 2009-01-30 JP JP2010544810A patent/JP2011510650A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110190143A1 (en) | 2011-08-04 |
| EP2085486A1 (en) | 2009-08-05 |
| WO2009095786A2 (en) | 2009-08-06 |
| EP2245194A2 (en) | 2010-11-03 |
| WO2009095786A3 (en) | 2009-11-05 |
| JP2011510650A (ja) | 2011-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2713839A1 (en) | Methods and kits for the rapid determination of patients at high risk of death during septic shock | |
| US11072830B2 (en) | Methods for breast cancer risk assessment | |
| US20210087632A1 (en) | Diagnosis of sepsis | |
| US7604936B2 (en) | Methods and compositions for diagnosis and monitoring auto immune and chronic inflammatory diseases | |
| US20120245235A1 (en) | Classification of cancers | |
| US20140342924A1 (en) | Molecular Diagnostic Test for Cancer | |
| KR102334702B1 (ko) | 유방암 발생 위험의 평가 방법 | |
| AU2016228508A1 (en) | Methods for diagnosis of sepsis | |
| JP2013066474A (ja) | 血液白血球中の遺伝子発現サインが、急性感染の差次的診断を可能にする | |
| US11053551B2 (en) | Method and apparatus for determining a probability of colorectal cancer in a subject | |
| CN101208602A (zh) | 脓毒症的诊断 | |
| US20220235417A1 (en) | Biomarkers for assessing idiopathic pulmonary fibrosis | |
| US20100304987A1 (en) | Methods and kits for diagnosis and/or prognosis of the tolerant state in liver transplantation | |
| US20120264633A1 (en) | Methods for detecting thrombocytosis using biomarkers | |
| US20240018602A1 (en) | Polymorhpism detection for glioblastoma detection and treatment | |
| KR20230039213A (ko) | 뇌졸중 진단용 단일염기다형성 마커 및 이를 이용한 뇌졸중 진단 방법 | |
| HK1155781A (en) | Method and apparatus for determining a probability of colorectal cancer in a subject | |
| HK1168387B (en) | Methods for breast cancer risk assessment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20131217 |
|
| FZDE | Discontinued |
Effective date: 20170217 |